21st Century Business Herald reporters Zhu Ping, Lin Yunxiao, and Xi Lei Ye report from Beijing
@关于医药上市公司预警: Chipscreen Biosciences responded to the question of whether chidamide breast cancer indications are included in medical insurance on the interactive platform, saying that chidamide breast cancer indications are not included in medical insurance.
@关于医药上市公司动态: In terms of clinical/R&D/market progress, Tonghua Dongbao completed the enrollment of the first subject in the phase Ia clinical trial of GLP-1/GIP dual-target receptor agonist (THDBH120 for injection), and the R&D projects reserved by the Blue Biosynthetic Biotechnology Innovation Laboratory were relatively small, and the first-line maintenance treatment of KC1036 combined with PD-1 antibody obtained the clinical trial notice for the first-line maintenance treatment of locally advanced or metastatic esophageal squamous cell carcinoma. There is still uncertainty about the approval and timing of the 9-valent HPV vaccine of Wantai Biologics, Humanwell Pharmaceutical's eicosapentaenoic acid ethyl ester soft capsule has obtained the US FDA approval number, and the new drug application of Zhongsheng Pharmaceutical's onladivir tablets (ZSP1273 tablets) has been accepted; in terms of R&D projects, Aojing Medical has received a notice of national major project approval; in terms of share repurchase/pledge/transaction, Betta Pharmaceutical's shareholders' share pledge has changed, and the controlling shareholder of International Medical has carried out a stock pledge repurchase transaction. Yaokang Biotechnology plans to repurchase the company's shares with 20 million yuan to 40 million yuan, the chairman of Jiuzhou Pharmaceutical proposes to repurchase the company's shares by 50 million yuan to 100 million yuan, and Samsung Medical buys back the company's shares for the first time in a centralized bidding transaction.
Early warning on listed pharmaceutical companies
Chipscreen Biosciences: Chidamide breast cancer indications are not included in medical insurance
On December 25, Chipscreen Biosciences responded to the question of whether chidamide breast cancer indications should be included in the medical insurance on the interactive platform, saying that according to the notice of the National Health Insurance Administration and the Ministry of Human Resources and Social Security on the issuance of the "National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalogue (2023)", the company's product chidamide tablets were successfully negotiated and renewed, and were included in the 2023 medical insurance catalog, and the indications are limited to relapsed or refractory peripheral T who have received at least one prior systemic chemotherapy Patients with cellular lymphoma (PTCL) who were not included in the breast cancer indication.
About the dynamics of listed pharmaceutical companies
- Clinical/R&D/Market Progress
Tonghua Dongbao: Completed the enrollment of the first patient in the phase Ia clinical trial of GLP-1/GIP dual-target receptor agonist (THDBH120 for injection).
Tonghua Dongbao announced on December 26 that the phase Ia clinical trial of GLP-1/GIP dual-target receptor agonist (THDBH120 for injection) completed the enrollment of the first subject.
Blue Biotech: The synthetic biotechnology innovation laboratory has fewer R&D projects and a smaller amount of investment
According to the announcement released by Blue Biotech on December 26, the synthetic biotechnology innovation laboratory disclosed in the company's previous regular report is mainly used for the research and development of functional proteins, sweeteners, etc., but the reserve of research and development projects is small, the investment amount is small, and it is still in the early stage of research and development, and does not yet have the conditions for industrialization.
Khotstar Pharmaceutical: KC1036 in combination with PD-1 antibody for first-line maintenance treatment of locally advanced or metastatic esophageal squamous cell carcinoma obtained clinical trial notice
Kangchen Pharmaceutical announced on December 26 that the company received the "Notice of Clinical Trial" approved and issued by the National Medical Products Administration for the first-line maintenance treatment of locally advanced or metastatic esophageal squamous cell carcinoma.
Wantai Bio: There is still uncertainty about the approval of the company's nine-valent HPV vaccine and the timing of approval
Wantai Biotech announced on December 26 that the on-site work of the V8 phase of the phase III main clinical trial of the company's nine-valent HPV vaccine has been completed, and specimen testing is underway. According to the current national regulations on vaccine registration management, there is still uncertainty about the approval and approval time of the company's 9-valent HPV vaccine.
Humanwell Pharmaceutical: Eicosapentaenoic acid ethyl ester soft capsule obtained the US FDA approval number
Humanwell Pharmaceutical announced on December 26 that ethyl eicosapentaenoic acid soft capsules have obtained the US FDA approval number.
Zhongsheng Pharmaceutical: The new drug application of onladivir tablets (ZSP1273 tablets) was accepted
Zhongsheng Pharmaceutical announced on December 26 that the new drug marketing application of onladivir tablets (ZSP1273 tablets) was accepted.
- R&D projects
Aojing Medical: Received the notice of national major project approval
According to the announcement issued by Aojing Medical on December 26, it recently received the document of the Ministry of Science and Technology issued by the China Biotechnology Development Center "Notice on the 2023 Annual Project Arrangement Publicity of the Key Special Project of the National Key R&D Program "Diagnosis and Treatment Equipment and Biomedical Materials", which determined that the project of "Personalized Cranial Bionic Composite Repair Materials with Guided Bone Regeneration Function" issued by the company as the lead undertaking unit was selected as a key project of "Diagnosis and Treatment Equipment and Biomedical Materials".
- Share buyback/pledge/transaction
Betta Pharmaceutical: Changes in shareholders' share pledges
Betta Pharmaceuticals announced on December 26 that Betta Pharmaceuticals received a letter from its shareholder Ningbo Kaiming Investment Management Partnership (Limited Partnership) today, and learned that some of the shares held by Kaiming Investment in the company had undergone pledge changes. As of the disclosure date of this announcement, the cumulative number of pledged shares of the company's controlling shareholders and their concerted actors accounted for 54.44% of the number of shares of the company held by them, in addition, the change in share pledge does not involve pledge financing to meet the needs of the production and operation of listed companies; the cumulative number of pledged shares due in the next six months by the company's controlling shareholders and their concerted actors is 16,000,000 shares, accounting for 17.59% of its shares, accounting for 3.82% of the company's total share capital, and the corresponding financing balance is 30. 0.5 million yuan, the cumulative number of pledged shares due in the next year (excluding the aforementioned expiration in the next six months and this addition) is 32,652,471 shares, accounting for 35.89% of its shares, accounting for 7.80% of the company's total share capital, and the corresponding financing balance is 697.872 million yuan.
International Medical: The controlling shareholder conducts a stock pledge repurchase transaction
Xi'an International Medical announced on December 26 that it had recently received a notice from its controlling shareholder, Shaanxi Century New Century Commercial Management Co., Ltd. (hereinafter referred to as "Century New Dollar"), that Century New Dollar had recently handled a deferred repurchase and supplementary pledge of the stock pledge repurchase transaction between it and Zheshang Securities Co., Ltd., which held part of the company's shares.
Yaokang Biological: It is planned to repurchase the company's shares for 20 million yuan to 40 million yuan
Yaokang Biotech announced on December 26 that it intends to repurchase the company's shares for 20 million yuan to 40 million yuan, and the repurchase price will not exceed 29 yuan per share (inclusive).
Jiuzhou Pharmaceutical: The chairman proposed to repurchase the company's shares by 50 million yuan to 100 million yuan
Jiuzhou Pharmaceutical announced on December 26 that the chairman proposed to repurchase the company's shares by 50 million yuan to 100 million yuan.
Samsung Healthcare: Repurchasing the company's shares for the first time through centralized auction transactions
According to the announcement issued by Samsung Healthcare, on December 26, 2023, the company repurchased 949,950 shares of the company for the first time through centralized bidding transactions, accounting for 0.07% of the company's current total share capital of 1,412,070,071 shares, the highest price of the repurchase transaction is 19.80 yuan / share, the lowest price is 19.30 yuan / share, and the total amount of funds paid is 18,586,808.50 yuan (excluding stamp duty and transaction commissions and other expenses).
For more information, please download the 21 Finance APP